Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

BioMarin Pharmaceutical Inc. (BMRN) had Revenue of $745.14M for the most recently reported fiscal quarter, ending 2025-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-03-31

Income Statement Financials
Revenue	$745.14M
Net Income	$185.69M
Cost of Goods Sold	$151.56M
Gross Profit	$593.59M
Operating Expenses	$521.25M
Operating Income	$223.89M
Non-Operating Income/Expense	$14.20M
Pre-Tax Income	$238.09M
Normalized Pre-Tax Income	$238.09M
Income after Taxes	$185.69M
Income from Continuous Operations	$185.69M
Consolidated Net Income/Loss	$185.69M
Normalized Income after Taxes	$185.69M
EBIT	$223.89M
EBITDA	$244.60M
Weighted-Average Shares Outstanding (Basic)	190.97M
Weighted-Average Shares Outstanding (Diluted)	196.47M
Earnings per Share (EPS) (Basic)	$0.97
Earnings per Share (EPS) (Diluted)	$0.95
Balance Sheet Financials
Current Assets	$3.47B
Property, Plant, and Equipment	$1.03B
Long-Term Assets	$3.68B
Total Assets	$7.15B
Current Liabilities	$628.21M
Long-Term Debt	$595.65M
Long-Term Liabilities	$725.34M
Total Liabilities	$1.35B
Common Equity	$5.79B
Tangible Shareholders Equity	$5.35B
Shareholders Equity	$5.79B
Common Shares Outstanding	191.76M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$174.39M
Cash Flow from Investing Activities	$-28.24M
Cash Flow from Financial Activities	$-38.78M
Beginning Cash	$942.84M
End Cash	$1.05B
Increase/Decrease in Cash	$105.96M
Stock-Based Compensation	$37.70M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	5.52
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.09
Debt to Equity Ratio	0.10
Gross Margin	79.66%
Operating Margin	30.05%
EBIT Margin	30.05%
EBITDA Margin	--
Pre-Tax Profit Margin	31.95%
Profit Margin	24.92%
Free Cash Flow	$157.63M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.10
Inventory Turnover	0.12
Receiveable Turnover	1.01
Days Sales in Receivables	89.28
Return on Equity	3.21%
Return on Tangible Equity	3.47%
Return on Assets	2.60%
Return on Investments	2.91%
Book Value Per Share	$30.21
Free Cash Flow per Share	$0.80
Operating Cash Flow per Share	$0.89

Data from Zacks Investment Research, Inc.